NEW YORK, June 10, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding Covance Inc. (NYSE: CVD), PerkinElmer Inc. (NYSE: PKI), PAREXEL International Corporation (NASDAQ: PRXL), Analogic Corporation (NASDAQ: ALOG) and Alere Inc. (NYSE: ALR). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3535-100free.
--
Covance Inc. Analyst Notes
On June 5, 2014, Covance Inc. (Covance) stock increased slightly to end the day at $87.09 compared to the previous day's closing price at $85.89, representing a 1.4% growth. The Company's stock increased 4.1% over the past three trading days, compared to the Dow Jones Industrial Average which rose 0.55% and to the S&P 500 which rose 0.65% during the same trading period. The full analyst notes on Covance are available to download free of charge at:
http://www.analystsreview.com/Jun-10-2014/CVD/report.pdf
--
PerkinElmer Inc. Analyst Notes
On June 3, 2014, PerkinElmer Inc. (PerkinElmer) announced that it has entered into an agreement to collaborate with China's National Health and Family Planning Commission (NHFPC) for the development and implementation of an extensive three-year newborn screening training program focused on early detection of life-threatening disorders in an effort to improve millions of lives across rural China. Jim Corbett, President, Human Health, PerkinElmer, commented, "As birth rates continue to rise in China and demand for greater access to newborn screening in rural areas increases, PerkinElmer is responding with the advanced detection technologies, knowledge and infrastructure that can help the NHFPC achieve better outcomes." The project will leverage PerkinElmer's innovative diagnostics technologies and expertise in setting up and rolling out comprehensive newborn screening programs in rural areas. The full analyst notes on PerkinElmer are available to download free of charge at:
http://www.analystsreview.com/Jun-10-2014/PKI/report.pdf
--
PAREXEL International Corporation Analyst Notes
On June 2, 2014, PAREXEL International Corp. (PAREXEL) announced the authorization of the Company's Board of Directors on a stock repurchase program. The Board has authorized the repurchase of up to $150 million of the Company's common stock. The program has no set expiration date. Mr. Josef von Rickenbach, Chairman and CEO of PAREXEL stated, "We are committed to optimizing the capital structure of the Company and to creating and enhancing shareholder value. We're pleased that the strength of our business fundamentals allows us to demonstrate our confidence through this stock repurchase program. We remain positive about the long-term growth and profitability opportunities that lie ahead of us, and look forward to keeping shareholders apprised of our progress." The Company stated that it intends to use cash on hand, cash generated from operations, existing credit facilities or other financing to fund the share repurchase program. The full analyst notes on PAREXEL are available to download free of charge at:
http://www.analystsreview.com/Jun-10-2014/PRXL/report.pdf
--
Analogic Corporation Analyst Notes
On June 5, 2014, Analogic Corp. (Analogic) announced the authorization of the Company's Board of Directors on an additional repurchase program of up to $30 million of the Company's common stock. The repurchase program will be funded using the Company's available cash. Jim Green, Analogic's President and CEO, commented, "Our decision to implement this new stock repurchase program reflects our view of the long-term value of Analogic. We believe this plan is an appropriate use of our available cash and is in the best interest of our company and shareholders." As of April 30, 2014, Analogic had cash and cash equivalents of approximately $119 million and had approximately 12.4 million shares of common stock outstanding. The full analyst notes on Analogic are available to download free of charge at:
http://www.analystsreview.com/Jun-10-2014/ALOG/report.pdf
--
Alere Inc. Analyst Notes
On June 5, 2014, Alere Inc.'s (Alere) stock declined slightly to end the day at $36.38, compared to the previous day's closing price at $36.52, which represents a 0.38% decrease. The Company's stock grew 1.14% over the past five trading days, compared to the Dow Jones Industrial Average which rose 0.82% and to S&P 500 which rose 1.06% over the same trading period. The full analyst notes on Alere are available to download free of charge at:
http://www.analystsreview.com/Jun-10-2014/ALR/report.pdf
--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
